Who
Kathleen D. Scott
Director
Company insider
Files Form 4 as: Director, Dermata Therapeutics; Chief Financial Officer, ARS Pharmaceuticals; Director, NKGen Biotech; Director, Conatus Pharmaceuticals.
In numbers
- Trades disclosed
- 34
- Buys
- 1
- Sells
- 5
- Bought
- $51K
- Sold
- $1.3M
- Companies
- 4
- Companies where not an officer
- 3
- First trade
- 18 Nov 2019
- Last trade
- 16 Jun 2026
- Last filed
- 16 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 16 Jun 2026filed 16 Jun 2026 | DRMA Dermata TherapeuticsBiotechnology | SEC FORM 4 Sold | $1311 at $1.19 | filing |
| 16 Jun 2026filed 16 Jun 2026 | DRMA Dermata TherapeuticsBiotechnology | SEC FORM 4 Sold | $1311 at $1.19 | filing |
| 2 Jan 2026filed 6 Jan 2026 | DRMA Dermata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | DRMA Dermata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —240,000 at $0.00 | filing |
| 2 Jan 2026filed 5 Jan 2026 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —240,000 at $0.00 | filing |
| 21 Aug 2025filed 22 Aug 2025 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
| 21 Aug 2025filed 22 Aug 2025 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $19K12,500 at $1.50 | filing |
| 21 Aug 2025filed 22 Aug 2025 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $188K12,500 at $15.00 | filing |
| 20 May 2025filed 22 May 2025 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —50,000 at $0.00 | filing |
| 20 May 2025filed 22 May 2025 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $75K50,000 at $1.50 | filing |
| 20 May 2025filed 22 May 2025 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $705K50,000 at $14.10 | filing |
| 13 Jan 2025filed 14 Jan 2025 | DRMA Dermata Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,000 at $0.00 | filing |
| 2 Jan 2025filed 3 Jan 2025 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —176,700 at $0.00 | filing |
| 6 Dec 2024filed 10 Dec 2024 | NKGen Biotechoption or derivative | SEC FORM 4 Code A | —300,000 at $0.00 | filing |
| 6 Dec 2024filed 10 Dec 2024 | NKGen Biotechoption or derivative | SEC FORM 4 Code A | —500,000 at $0.00 | filing |
| 16 Oct 2024filed 17 Oct 2024 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
| 16 Oct 2024filed 17 Oct 2024 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Code M | $19K12,500 at $1.50 | filing |
| 16 Oct 2024filed 17 Oct 2024 | SPRY ARS PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $200K12,500 at $16.00 | filing |
| 20 Aug 2024filed 21 Aug 2024 | SPRY ARS Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —12,500 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.